EAM Global Investors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

EAM Global Investors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,137	Closed	-$1.69M	–	291
2021 Q3	$1.69M	Buy	+12,137	New	+$1.52M	0.4%	117
2019 Q3	–	Sell	-42,238	Closed	-$1.85M	–	168
2019 Q2	$1.85M	Hold	42,238	–	–	0.79%	43
2019 Q1	$2.17M	Buy	+42,238	New	+$1.82M	0.96%	25

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM Global Investors's BHVN Position: Q4 2021 in Review

EAM Global Investors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2021, closing a stake of 12,137 shares — an estimated $1.69M sold.

EAM Global Investors first reported a position in BHVN in Q1 2019 and held it in 3 quarters. The position peaked at $2.17M in Q1 2019. 284 funds tracked by Wall St. Rank hold BHVN as of Q4 2021.

EAM Global Investors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2021 after selling out during the quarter.
EAM Global Investors sold 12,137 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2021, an estimated $1.69M.
EAM Global Investors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 3 quarters.
EAM Global Investors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.17M in Q1 2019.
284 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2021.

Based on EAM Global Investors's 13F filing for Q4 2021, filed 11 Feb 2022.